Skip to main content
PEPTARA LABS
Get Started

Topic hub: fat loss

Best Peptides for Fat Loss: Ranked by Trial Effect Size

Published by · Updated · How we research and check our pages

Peptides for fat loss: six compounds ranked by trial body-weight reduction. From -24.2% Phase 2 (retatrutide) to preclinical-only (SLU-PP-332). Vendor-neutral. Includes FDA status, monthly cost, and a goal-based decision tree.

Verdict in 5 lines

  • Biggest trial effect: Retatrutide -24.2% body weight in the highest dose group (Phase 2, NEJM 2023).
  • Biggest FDA-approved effect: Tirzepatide -22.5% in the highest dose group (Phase 3 SURMOUNT-1, NEJM 2022).
  • Longest safety record: Semaglutide -14.9% (Phase 3 STEP-1, NEJM 2021). Peptara does NOT sell semaglutide.
  • Visceral-fat-specific: Tesamorelin -15% VAT (not total body weight) at 2mg/day (Phase 3, NEJM 2007).
  • Different trials, different cohorts, different durations. Effect-size comparison across trials is a directional observation, not a controlled head-to-head finding.

Ranked by trial effect size

Sourced from peer-reviewed clinical trials (NEJM 2007, 2021, 2022, 2023). Effect-size comparisons across separate studies are directional, not controlled head-to-head.

RankPeptidePeak Trial EffectPhase / SourceFDA Status (obesity)Peptara Cost after the sale (email signup)
1Retatrutide-24.2% body weightPhase 2
Jastreboff et al, NEJM 2023
Research compound. Phase 3 ongoing.Not sold by Peptara
2Tirzepatide-22.5% body weightPhase 3
Jastreboff et al, NEJM 2022 (SURMOUNT-1)
Zepbound FDA-approved Nov 2023 (brand pen).Not sold by Peptara
3Semaglutide (Ozempic / Wegovy)-14.9% body weightPhase 3
Wilding et al, NEJM 2021 (STEP-1)
Wegovy FDA-approved Jun 2021NOT sold by Peptara. US retail $968 to $1,349/mo
4Tesamorelin-15% visceral adipose tissue (VAT)Phase 3
Falutz et al, NEJM 2007
FDA-approved 2010 (HIV-associated lipodystrophy). Off-label / research for general VAT.about $440/mo with email signup (1mg/day)
5MOTS-cMetabolism + insulin sensitivity (no Phase 3 obesity trial)Preclinical + small human
Lee et al, Cell Metab 2015
Research compound$85 to $170/mo with email signup (5 to 10mg/wk)
6SLU-PP-332Exercise mimetic (no human obesity trials)Preclinical (mouse only)
Billon et al, J Pharmacol Exp Ther 2023
Research compound$157/vial with email signup, biohacker dosing varies

Read this before quoting the ranking

Different trials, different cohorts, different durations, different placebo response calibration. These effect sizes are a directional comparison across separate studies, not a controlled head-to-head finding. Retatrutide Phase 3 results from the TRIUMPH program may report different numbers than Phase 2. SURMOUNT-1 ran 72 weeks; STEP-1 ran 68 weeks. Tesamorelin measured visceral fat (VAT) not total body weight, which is a different endpoint.

Decide by goal

Six goal profiles. Find the card that matches what you actually care about.

Goal A

Biggest weight loss number

Triple-agonist GLP-1 + GIP + glucagon. Largest trial effect (-24.2% Phase 2). Trade-off: Phase 3 still collecting. Research compound, not FDA-approved.

Largest trial effect: Retatrutide (investigational, not sold by Peptara)

Goal B

FDA-approved, longest safety record

Single-agonist GLP-1. Years of cardiovascular outcome data (SUSTAIN, SELECT). Trade-off: smallest trial effect of the GLP-1 class (-14.9% STEP-1). US retail $968 to $1,349/mo cash. Peptara does NOT sell semaglutide.

Pick: Semaglutide (Ozempic / Wegovy)

Goal C

FDA-approved, biggest trial effect

Dual-agonist GLP-1 + GIP. -22.5% Phase 3 SURMOUNT-1. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023).

Largest approved effect: Tirzepatide (Zepbound, prescription only)

Goal D

Belly / visceral fat specifically

GHRH analog. Stimulates pulsatile GH leading to IGF-1 leading to preferential VAT reduction. Different endpoint: -15% visceral adipose tissue (NOT total body weight). FDA-approved 2010 (Egrifta) for HIV-associated lipodystrophy. Used off-label or research for visceral fat in non-HIV populations.

Pick: Tesamorelin

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Goal E

Metabolism + insulin sensitivity, no GLP-1 GI

Mitochondrial-derived peptide. Boosts cellular energy and insulin sensitivity. Fat-loss-adjacent, not primary fat-loss. No Phase 3 obesity trial. Preclinical plus small human studies on aging and metabolism.

Pick: MOTS-c

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Goal F

Endurance / fat oxidation, not appetite suppression

ERR receptor agonist. Exercise-in-a-vial mechanism. Preclinical mouse data only. NO human obesity trials. For research / biohacker use, not validated for fat loss in humans.

Pick: SLU-PP-332

Available via Peptara, no dedicated product page yet. Contact WhatsApp.

Mechanism groups

Three biological pathways, six compounds.

GLP-1 class (appetite + metabolic)

Retatrutide (triple agonist), Tirzepatide (dual), Semaglutide (single). Activate the gut-brain satiety axis plus insulin / glucagon regulation. Mechanism of action shared; receptor count differs.

GH axis (visceral fat-specific)

Tesamorelin (GHRH analog). Stimulates endogenous GH release leading to IGF-1 leading to preferential visceral adipose tissue reduction. Different endpoint than GLP-1s.

Mitochondrial / exercise mimetic

MOTS-c (mitochondrial peptide), SLU-PP-332 (ERR agonist). Boost cellular energy and fat oxidation. Less validated for fat loss; closer to metabolic optimization. Emerging class.

Cost breakdown

These ranges use the email-signup rate, which comes back after the Black Friday sale; until November 30 each vial is 45% to 60% off by how many are in the cart. Peptara monthly cost ranges with the email-signup rate applied. Cost formula: vial price times 4.33 weeks per month, divided by weeks per vial.

PeptideVialEmail signup / Retail, after the saleCommon DoseMonthly email rate, after the saleMonthly regular retail
Tesamorelin10mg$144 / $1701mg/day common researchabout $440about $515
MOTS-c40mg$157 / $1855 to 10mg/wkabout $85 to $170about $100 to $200
SLU-PP-3325mg$157 / $185Research-only, variesVariesVaries

External US retail reference (not Peptara pricing)

Ozempic about $968/mo, Wegovy about $1,349/mo (Novo Nordisk cash list). Compounded semaglutide about $200 to $400/mo (FDA-restricted after October 2024 shortage resolution). Peptara does NOT sell semaglutide.

Monthly cost calculation: vial price times 4.33 weeks/month divided by weeks per vial. Doses always in units, never mL. See the reconstitution guide for full math.

Stacking framework

What to combine, what to avoid, how to sequence.

Smart stacks

  • GLP-1 plus CJC-1295 / Ipamorelin (lean mass retention during fat loss). See the research stacks.

Avoid

  • Two GLP-1 agonists together (redundant mechanism, additive GI side effects)

Sequencing

  • Stopping a GLP-1 is followed by appetite and glucose homeostasis adjustment, a question for the prescribing clinician

FDA status and regulatory landscape

Two FDA-approved as brand pens (Tirz, Sema). One FDA-approved for a specific non-obesity indication (Tesamorelin, HIV-associated lipodystrophy). Three research compounds.

PeptideStatusFDA Approval DateAvailable Form
RetatrutideResearch compoundPhase 3 ongoing (TRIUMPH program)None approved (investigational)
TirzepatideFDA-approved (brand pens)Mounjaro May 2022 (T2D), Zepbound Nov 2023 (obesity)Brand pre-filled pen via Rx
Semaglutide (Ozempic / Wegovy)FDA-approved (brand pens)Ozempic Dec 2017, Wegovy Jun 2021Brand pre-filled pen via Rx ONLY. Peptara does not sell.
TesamorelinFDA-approved (Egrifta)Nov 2010FDA-approved for HIV-associated lipodystrophy. Off-label / research for general VAT reduction.
MOTS-cResearch compoundN/AResearch vial only
SLU-PP-332Research compoundN/AResearch vial only (preclinical data; not for clinical use)

Side effects by mechanism group

Three profiles to know.

GLP-1 class (retatrutide, tirzepatide, semaglutide)

Nausea, diarrhea, constipation, vomiting. In the trials these were most common in the higher dose groups and mostly mild to moderate. GLP-1 class carries thyroid C-cell black-box warning (rodent signal; no confirmed human cases). Trial-reported nausea rates: retatrutide about 30% in its highest dose group (Jastreboff et al., NEJM 2023), tirzepatide about 30% in its highest dose group (SURMOUNT-1, Jastreboff et al., NEJM 2022), semaglutide about 20% (STEP-1, Wilding et al., NEJM 2021).

GH-axis (Tesamorelin)

Injection-site reactions, joint pain, fluid retention. May elevate IGF-1 (monitor lab values for longer protocols). Avoid in active malignancy and diabetic retinopathy.

Mitochondrial + exercise mimetic (MOTS-c, SLU-PP-332)

Limited human data. MOTS-c well-tolerated in small studies. SLU-PP-332 long-term human safety not established (preclinical only). Standard research-compound caveats apply.

Frequently asked questions

Which peptide loses the most weight?

Retatrutide showed the largest mean body-weight reduction in trials at -24.2% over 48 weeks (Jastreboff et al, Phase 2, NEJM 2023). Tirzepatide is the largest FDA-approved effect at -22.5% over 72 weeks (Jastreboff et al, Phase 3 SURMOUNT-1, NEJM 2022). Semaglutide (Ozempic / Wegovy) is -14.9% (Wilding et al, Phase 3 STEP-1, NEJM 2021). These are separate trials with different cohorts and different durations, so the comparison is a directional observation, not a controlled head-to-head finding.

Are GLP-1 peptides the only option for fat loss?

No. Tesamorelin (GHRH analog) is FDA-approved (2010) and targets visceral adipose tissue specifically, not total body weight. MOTS-c (mitochondrial peptide) and SLU-PP-332 (ERR agonist exercise mimetic) operate via different metabolic pathways. GLP-1 agonists (Reta, Tirz, Sema) currently produce the largest measured fat-loss effects, but they are not the only peptides studied for body-composition outcomes.

Does Peptara sell Ozempic or Wegovy?

No. Peptara does NOT sell semaglutide in any form. Peptara is a research-peptide supplier. Brand pens (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved finished pharmaceuticals available only via prescription. Anyone selling brand pens online is selling gray-market product with no chain-of-custody guarantee. Peptara stocks Tesamorelin, MOTS-c, and SLU-PP-332 as research vials.

What is the difference between visceral and subcutaneous fat loss?

Subcutaneous fat is the layer under the skin (what you can pinch). Visceral fat (VAT) is the deep abdominal fat surrounding internal organs; it is metabolically distinct and more strongly tied to insulin resistance, cardiovascular risk, and type 2 diabetes. GLP-1 agonists (Reta, Tirz, Sema) reduce both compartments via total body weight loss. Tesamorelin specifically targets VAT (-15% in Phase 3) without a comparable effect on subcutaneous fat.

Are there fat-loss peptides without GLP-1 side effects (nausea, etc.)?

Yes. Tesamorelin (GH axis), MOTS-c (mitochondrial), and SLU-PP-332 (ERR agonist) operate outside the GLP-1 pathway and do not share the appetite-mediated GI profile. Trade-off: smaller effect on total body weight than the GLP-1 class, and less clinical validation. Tesamorelin is the most validated non-GLP-1 option for fat-targeting (FDA-approved 2010 for VAT reduction).

How long did the fat-loss trials run?

Each trial on this page reported a group average at the end of a fixed study period, not a timeline for any one person. The semaglutide trial (Wilding et al, NEJM 2021, STEP-1) followed people for 68 weeks, and the tirzepatide trial (Jastreboff et al, NEJM 2022, SURMOUNT-1) for 72 weeks. The tesamorelin trial measured belly fat on scans after 26 weeks (Falutz et al, NEJM 2007). The MOTS-c work cited here was done mostly in mice, so it gives no human time frame (Lee et al, Cell Metab 2015).

Questions about these compounds

Message the Peptara team on WhatsApp and we will point you at what the research describes for each fat-loss compound.

We answer protocol questions, not medical questions. For Tesamorelin, MOTS-c, and SLU-PP-332 (no dedicated product page yet), WhatsApp is the order channel.

Chat with us